Structure Therapeutics (GPCR) has drawn attention after recent share price swings, including a month return of a 27.7% decline and a past 3 months gain of 80.8%, prompting investors to reassess its ...

Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap ...

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and ...

Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to ...

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands ...

Fintel reports that on May 2, 2025, Citigroup initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () (NasdaqGM:GPCR) with a Buy recommendation. As of April 24, 2025, the average one ...

Investors with a lot of money to spend have taken a bullish stance on Structure Therapeutics (NASDAQ:GPCR). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it’s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with ...